 Each cohort of subjects will be dosed sequentially approximately two weeks apart for the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of dosing for the multiple dose period. Each cohort of subjects in the multiple dose period will be dosed sequentially, approximately, one week apart, allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort. In the event of suspected drug related toxicity, as determined by the principal investigator, sponsor, and an independent medical monitor, at a dose of 0.03 gday, all subjects in the 0.03 gday cohort will discontinue dosing, and the subsequent cohort will receive 0.01 gday for seven consecutive days. Safety and PK-related data will be reviewed for the 0.01 gday dose level, and no subsequent cohorts will be enrolled into the study. 